Okyo Pharma Limited ADR (OKYO)

$2.39 +0.15 (6.70%)
Market Cap 89.89M
Revenue (ttm) 0.00
Net Income (ttm) -4.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 277,900
Avg Vol 138,974
Day's Range N/A - N/A
Shares Out 37.61M
Stochastic %K 86%
Beta -0.14
Analysts Sell
Price Target $7.00

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7495 2379
Address:
14/15 Conduit St, Floor 4, London, United Kingdom
rp6577
rp6577 Oct. 20 at 6:23 PM
$OKYO $3 is calling GC bought a good chunk last week. He sees the value
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 17 at 6:16 PM
$OKYO - expecting a run up here before end of year to new highs. Exciting stuff in the pipeline
0 · Reply
rp6577
rp6577 Oct. 17 at 6:12 PM
$OKYO heating up
0 · Reply
pAmdd
pAmdd Oct. 17 at 3:43 PM
$OKYO how is this even possible
0 · Reply
moosegoose
moosegoose Oct. 17 at 2:08 PM
$OKYO https://www.investing.com/news/sec-filings/okyo-pharma-executive-chairman-linked-entity-acquires-210000-shares-on-nasdaq-93CH-4292296
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 8 at 8:16 PM
$OKYO - back to $3 🔜 here 👀
1 · Reply
rp6577
rp6577 Oct. 8 at 2:33 PM
$OKYO 🔥
0 · Reply
WilliamsEmpire
WilliamsEmpire Oct. 7 at 9:00 PM
$OKYO how do we get updates on the 100 person trial?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 7:36 PM
$OKYO Excellent article that nails exactly where OKYO stands right now. So if you want to update your OKYO knowledge or get acquainted with OKYO, this is a must read. https://beyondspx.com/quote/OKYO/analysis/okyo-pharma-s-visionary-pivot-unlocking-neuropathic-corneal-pain-s-untapped-potential-nasdaq-okyo
1 · Reply
rp6577
rp6577 Oct. 3 at 2:12 PM
$OKYO strong support at $2
0 · Reply
Latest News on OKYO
OKYO Pharma Announces Chairman and Founder Acquires Shares

Oct 16, 2025, 8:30 AM EDT - 9 days ago

OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Sep 22, 2025, 8:30 AM EDT - 4 weeks ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jul 16, 2025, 9:21 AM EDT - 3 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

Jun 11, 2025, 10:05 AM EDT - 4 months ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

May 19, 2025, 7:00 AM EDT - 5 months ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Apr 30, 2025, 7:00 AM EDT - 6 months ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Mar 31, 2025, 8:00 AM EDT - 7 months ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 31, 2025, 7:00 AM EST - 9 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Jan 30, 2025, 9:45 AM EST - 9 months ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 15, 2024, 9:00 AM EST - 1 year ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

OKYO Pharma Announces Chairman Acquires Shares

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 12:13 PM EDT - 1 year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Aug 6, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 11, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Jul 10, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 30, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Apr 8, 2024, 7:00 PM EDT - 1 year ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Apr 2, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 22, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 21, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Mar 20, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Feb 9, 2024, 7:00 AM EST - 1 year ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Jan 5, 2024, 9:30 AM EST - 1 year ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Oct 9, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 15, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

OKYO Pharma Announces Public Offering of Ordinary Shares

Sep 13, 2023, 4:05 PM EDT - 2 years ago

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Sep 8, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 30, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Aug 15, 2023, 9:00 AM EDT - 2 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Jul 28, 2023, 5:25 PM EDT - 2 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 5:05 PM EDT - 2 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

Jul 28, 2023, 7:01 AM EDT - 2 years ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Jul 27, 2023, 11:30 AM EDT - 2 years ago

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

Jun 6, 2023, 9:30 AM EDT - 2 years ago

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

May 3, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

May 2, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

Apr 25, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Apr 18, 2023, 10:00 AM EDT - 2 years ago

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Notice of General Meeting and Publication of Circular

Apr 5, 2023, 2:00 AM EDT - 2 years ago

Notice of General Meeting and Publication of Circular

Notice of Intention to Delist From The London Stock Exchange

Apr 4, 2023, 2:00 AM EDT - 2 years ago

Notice of Intention to Delist From The London Stock Exchange

OKYO Pharma Today Announces Director Acquires Shares

Mar 30, 2023, 2:01 AM EDT - 2 years ago

OKYO Pharma Today Announces Director Acquires Shares

OKYO Pharma Announces PDMR Dealing

Mar 24, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Announces PDMR Dealing

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

Mar 16, 2023, 3:01 AM EDT - 2 years ago

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

Mar 14, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

Mar 13, 2023, 4:15 PM EDT - 2 years ago

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

rp6577
rp6577 Oct. 20 at 6:23 PM
$OKYO $3 is calling GC bought a good chunk last week. He sees the value
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 17 at 6:16 PM
$OKYO - expecting a run up here before end of year to new highs. Exciting stuff in the pipeline
0 · Reply
rp6577
rp6577 Oct. 17 at 6:12 PM
$OKYO heating up
0 · Reply
pAmdd
pAmdd Oct. 17 at 3:43 PM
$OKYO how is this even possible
0 · Reply
moosegoose
moosegoose Oct. 17 at 2:08 PM
$OKYO https://www.investing.com/news/sec-filings/okyo-pharma-executive-chairman-linked-entity-acquires-210000-shares-on-nasdaq-93CH-4292296
0 · Reply
Investing4Knowledge
Investing4Knowledge Oct. 8 at 8:16 PM
$OKYO - back to $3 🔜 here 👀
1 · Reply
rp6577
rp6577 Oct. 8 at 2:33 PM
$OKYO 🔥
0 · Reply
WilliamsEmpire
WilliamsEmpire Oct. 7 at 9:00 PM
$OKYO how do we get updates on the 100 person trial?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 7:36 PM
$OKYO Excellent article that nails exactly where OKYO stands right now. So if you want to update your OKYO knowledge or get acquainted with OKYO, this is a must read. https://beyondspx.com/quote/OKYO/analysis/okyo-pharma-s-visionary-pivot-unlocking-neuropathic-corneal-pain-s-untapped-potential-nasdaq-okyo
1 · Reply
rp6577
rp6577 Oct. 3 at 2:12 PM
$OKYO strong support at $2
0 · Reply
William_The_Great
William_The_Great Oct. 2 at 8:55 AM
$OKYO when is the next major update? November ?
0 · Reply
William_The_Great
William_The_Great Sep. 29 at 5:45 PM
$OKYO what’s a good time to enter ?
3 · Reply
rp6577
rp6577 Sep. 27 at 3:15 PM
$OKYO with regards the recently announced bed 100 patient trial, it is labeled a "registration pathway" trial. It’s therefore designed to generate the pivotal data needed for NDA submission—effectively serving as a Phase 2/3 hybrid or standalone confirmatory study
0 · Reply
Ventureville
Ventureville Sep. 24 at 4:24 PM
$OKYO Always comes back to execution. $BIOV still has DPX-SurMAGE and HapTenix active, just waiting on the right partners to push faster.
0 · Reply
Vinceofmaui
Vinceofmaui Sep. 24 at 1:50 PM
$PLUG OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug $OKYO https://stocktwits.com/news/equity/markets/okyo-pharma-stock-rises-after-company-outlines-development-pathway-for-neuropathic-corneal-pain-drug/chDQvHoR32v
0 · Reply
Oscarca
Oscarca Sep. 23 at 10:28 AM
$OKYO
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 22 at 5:35 PM
OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug $OKYO https://stocktwits.com/news/equity/markets/okyo-pharma-stock-rises-after-company-outlines-development-pathway-for-neuropathic-corneal-pain-drug/chDQvHoR32v
0 · Reply
rp6577
rp6577 Sep. 22 at 5:13 PM
$OKYO starting to rally of that bottom $XBI
0 · Reply
Oscarca
Oscarca Sep. 22 at 2:55 PM
$OKYO https://www.globenewswire.com/news-release/2025/09/22/3153922/0/en/OKYO-Pharma-Announces-Registration-Pathway-with-100-Patient-Multi-Center-Clinical-Trial-of-Urcosimod-in-Neuropathic-Corneal-Pain.html?fbclid=IwdGRjcAM-QopleHRuA2FlbQIxMQABHlzQ5mvMCU2xcb8ukxyoCMDS_cK2OhcJJX0IWTO8-tY9HXuKOEkAFzuZ-noi_aem_gMxT8MfLq3KEiklmHpKQZw
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 22 at 12:39 PM
$OKYO OKYO Pharma Announces Plans For Next Stage Of Clinical Development For Lead Drug Candidate, Urcosimod, To Treat Neuropathic Corneal Pain
0 · Reply
rp6577
rp6577 Sep. 22 at 12:33 PM
$OKYO exactly what we were waiting for! Clear route forward, which is exactly what a big Pharma partner needs
0 · Reply
rp6577
rp6577 Sep. 20 at 9:35 PM
$OKYO could get very interesting from here
0 · Reply